Stability of Von Willebrand factor and factor VIII in different storage protocols of canine cryoprecipitate

• Grant number: 12/15219-5
• Support Opportunities: Regular Research Grants
• Start date: October 01, 2012
• End date: September 30, 2014
• Field of knowledge: Agronomical Sciences - Veterinary Medicine - Animal Clinics and Surgery
• Principal Investigator: Regina Kiomi Takahira
• Grantee: Regina Kiomi Takahira
• Host Institution: Faculdade de Medicina Veterinária e Zootecnia (FMVZ). Universidade Estadual Paulista (UNESP). Campus de Botucatu. Botucatu , SP, Brazil

Abstract

The factor VIII (FVIII), von Willebrand factor (vWF) and fibrinogen are extremely important in blood coagulation, with different physiological functions. Due to its higher concentrations of FVIII, von Willebrand factor (vWF), fibrinogen and factor XIII, the transfusion of cryoprecipitate is a therapy mainly recommended in patients with von Willebrand Disease, Hemophilia A (FVIII deficiency), or patients undergoing hypo or dysfibrinogenemia. This blood component is a precipitate obtained after partial thawing (between 1 and 6 ° C) of fresh frozen plasma, and is also known as antihemophilic factor. Studies have shown that the freezing and storage protocols of cryoprecipitate affect the product quality and the viability of these factors. In order to assess the viability of canine cryoprecipitate in different freezing and storage protocols two groups composed of 10 units of canine cryoprecipitate will be evaluated (n=20). After centrifugation of the bags, the fresh plasma of the group I will be frozen at - 80°C and at -20°C in group II. Twenty-four hours after freezing, they will be subjected to the standard procedure of cryoprecipitate extraction. The cryoprecipitate of both groups will be evaluated by the determination of PT, APTT, FVIII, vWF and fibrinogen concentrations after zero, six and twelve months of storage. The evaluation of the effects of the freezing temperature and time of storage of the cryoprecipitate will be performed by ANOVA at the 5% significance level. (AU)